ArticlePharmacoepidemiology and drug safety2024

Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.

Yoon Duk Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.